Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Advertising
 

EquipNet Auction: Sell Your Surplus Equipment on Our Global Marketplace Now!

Our Newest Cartoon Illustrates: "The Biology of Valentines"


Washington Life Science Industry Directory

World Blood Donor Day

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

CytoDyn Inc.


CytoDyn Inc.
1111 Main Street, Suite 660
Vancouver, WA 98660
CytoDyn Inc.
 
Phone: (360) 980-8524
Year Established:  1994
Ticker: CYDY
Exchange: OTCQB
Main Contact: Nader Z. Pourhassan, Ph.D., President & CEO
 
Other Contacts:  Anthony D. Caracciolo, Chairman
Michael D. Mulholland, CFO
Richard G. Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., CMO
 
Company Description
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has finished Phase 2 clinical trials with demonstrated antiviral activity in man and is currently in Phase 3. PRO 140 blocks the HIV co-receptor CCR5 on T-cells which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from six Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several weeks of interruption from conventional drug therapy. CytoDyn intends to continue to develop PRO 140 as a therapeutic anti-viral agent in persons infected with HIV.


Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.